DengyueMed Report: China's National Medical Products Administration has conditionally approved a milestone antitumor new drug—Glumetinib Tablets (trade name: Haiyitan®)—for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping (METex14 skipping). This breakthrough advancement marks a key step...